Developer docs
API playgroundTry for free, no card

Search company profiles

Liquidia Technologies

Full company profile

uuid000221i

Namestring
Liquidia Technologies
Legal namestring
Liquidia Corporation
Websiteurl
liquidia.com
Company typeenum
Public
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled treprostinil therapy, pulmonary hypertension drugs, biopharmaceutical drug delivery, PRINT particle engineering, rare cardiopulmonary therapeutics
Industry2 codes
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Pulmonary Hypertension Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1YUTREPIA Product Sales
TypeOne Time License
Description

Revenue from direct sales of FDA-approved YUTREPIA (treprostinil) inhalation powder for treatment of PAH and PH-ILD. Product launched June 2025 following FDA approval.

globenewswire.com
2Treprostinil Injection Promotion
TypeProfessional Services
Description

Service revenue from promotion agreement with Sandoz Inc. sharing profits from sale of generic Treprostinil Injection in the United States.

liquidia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1Prescription pharmaceutical product - pricing determined through insurance coverage and patient assistance programs
ModelOtherBilling cadenceMonthly
Notes

YUTREPIA is dispensed through specialty pharmacies with pricing based on individual insurance coverage, patient assistance programs, and standard pharmaceutical pricing mechanisms.

liquidia.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1YUTREPIA
Description

FDA-approved inhaled dry-powder formulation of treprostinil for treatment of PAH and PH-ILD, delivered through a palm-sized device using PRINT technology

liquidia.com
+3 more records
Core offering1 text field

Liquidia Corporation is a biopharmaceutical company that develops and commercializes inhaled therapeutics for rare cardiopulmonary diseases. Its lead commercial product is YUTREPIA (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), delivered via a palm-sized low-resistance device built on the company's proprietary PRINT particle engineering platform. The company also promotes a generic Treprostinil Injection with partner Sandoz and is developing L606, an investigational sustained-release liposomal treprostinil inhalation suspension.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced coughing and improved tolerability in PH-ILD patients over 24 weeks of treatment
+1 more record
Product overview1 text field

Liquidia Corporation is a biopharmaceutical company focused on rare cardiopulmonary diseases, operating a portfolio of commercial and pipeline products. The commercial portfolio includes YUTREPIA™ (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for PAH and PH-ILD launched in June 2025, and Treprostinil Injection, a generic formulation promoted with partner Sandoz. The pipeline includes L606, an investigational extended-release liposomal formulation of treprostinil administered twice-daily via nebulizer, currently in pivotal Phase 3 trials (Re-Spire). All products leverage the company's proprietary PRINT® technology platform for enhanced drug delivery.

Product and service2 records
1YUTREPIA (treprostinil) Inhalation Powder
CategoryCommercial inhaled treprostinil therapy
Description

FDA-approved inhaled dry-powder formulation of treprostinil indicated for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Delivered through a convenient, low-resistance, palm-sized device using Liquidia's proprietary PRINT technology, with particles 1.3 μm in size precisely engineered with a trefoil shape for enhanced deep-lung deposition. For patients with WHO Group 1 PAH and WHO Group 3 PH-ILD and the pulmonologists, PH specialists, and specialty pharmacies who treat them.

2Treprostinil Injection
CategoryCommercial generic injectable treprostinil therapy
Description

Fully substitutable AP-rated generic formulation of Remodulin (treprostinil) Injection for treatment of pulmonary arterial hypertension (PAH). Liquidia promotes the product in the United States in conjunction with commercial partner Sandoz, Inc., which holds the ANDA with the FDA.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to develop L606 (liposomal treprostinil inhalation suspension), an investigational sustained-release formulation of treprostinil administered twice-daily via rapid nebulization with a hand-held portable system for PAH and PH-ILD treatment.

2Sandoz Inc.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partnership for Treprostinil Injection promotion in the United States. Sandoz holds the ANDA with the FDA for the generic formulation while Liquidia promotes appropriate use of the product.

liquidia.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor and the incumbent in inhaled treprostinil therapy with Tyvaso and Tyvaso DPI for PAH and PH-ILD. Head-to-head competitor to YUTREPIA in the same patient population and same drug class, and also the plaintiff in ongoing patent litigation against Liquidia.

TypeEmerging player
Description

Late-stage biopharma developing seralutinib (inhaled PDGF/CSF1R/VEGFR inhibitor) for PAH, including the Phase 3 TORREY study. Competes in the same PAH specialty channel and targets the same pulmonologists and PH specialists as YUTREPIA.

TypeBroad incumbent
Description

Respiratory-focused biopharma with Arikayce (approved) and brensocatib (Phase 3) in non-CF bronchiectasis and other pulmonary indications. Not a direct competitor in PAH but a broad respiratory player pursuing adjacent specialty pulmonology markets and competing for similar talent and clinical site infrastructure.

TypeEmerging player
Description

Private biotech developing inhaled imatinib (AER-901) for severe pulmonary diseases including PAH. Competes with YUTREPIA for the same PAH specialist audience with a different mechanism and overlapping clinical development timelines.

TypeBroad incumbent
Description

Markets Adempas (riociguat), the only approved therapy for chronic thromboembolic pulmonary hypertension (CTEPH) and an approved PAH therapy. A broad incumbent in the pulmonary hypertension space competing for prescriber share across multiple PH subtypes.

TypeBroad incumbent
Description

Acquired Acceleron Pharma in 2021 to obtain Winrevair (sotatercept), the first activin signaling inhibitor approved for PAH. Represents a major new mechanism-based competitor that could shift PAH treatment paradigms and indirectly pressure YUTREPIA's market position.

TypeEmerging player
Description

Clinical-stage biopharma developing inhaled imatinib (AV-101) for PH-ILD. Same pulmonary hypertension patient focus as YUTREPIA but with a different mechanism (tyrosine kinase inhibitor), competing for the same PH-ILD prescriber mind-share.

TypeEmerging player
Description

Clinical-stage company developing TNX-103 (oral levosimendan) for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Adjacent pulmonary hypertension franchise competing for the same specialist prescribers and clinical-development infrastructure as Liquidia.

TypeOthers
Description

Liquidia's co-development partner for L606 (liposomal treprostinil inhalation suspension). Adjacent rather than directly competitive; develops and supplies the liposomal formulation used in Liquidia's Phase 3 Re-Spire study, making it a key enabling partner in Liquidia's pipeline.

10Johnson & Johnson (Actelion)
TypeBroad incumbent
Description

Acquired Actelion in 2017 to gain the leading oral PAH franchise (Opsumit/macitentan, Tracleer/ bosentan, Uptravi/selexipag). A broad incumbent that competes with YUTREPIA for PAH patient starts and physician attention across multiple lines of therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Liquidia Technologies

Pulmonary Hypertension Therapeuticsliquidia.com

Liquidia Technologies firmographics

Firmographics
Name
Liquidia Technologies
Legal name
Liquidia Corporation
Website
https://liquidia.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Liquidia Technologies industry classification

Industry
Product category
Pulmonary Hypertension Therapeutics
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Inhaled treprostinil therapy
  • Pulmonary hypertension drugs
  • Biopharmaceutical drug delivery
  • PRINT particle engineering
  • Rare cardiopulmonary therapeutics

Where Liquidia Technologies is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Liquidia Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. YUTREPIA Product Sales: Revenue from direct sales of FDA-approved YUTREPIA (treprostinil) inhalation powder for treatment of PAH and PH-ILD. Product launched June 2025 following FDA approval.
  2. Treprostinil Injection Promotion: Service revenue from promotion agreement with Sandoz Inc. sharing profits from sale of generic Treprostinil Injection in the United States.

Pricing tiers

ModelBillingPrice
OtherMonthlyPrescription pharmaceutical product - pricing determined through insurance coverage and patient assistance programs

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Liquidia Technologies product offering

Product offering

Core offering

Liquidia Corporation is a biopharmaceutical company that develops and commercializes inhaled therapeutics for rare cardiopulmonary diseases. Its lead commercial product is YUTREPIA (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), delivered via a palm-sized low-resistance device built on the company's proprietary PRINT particle engineering platform. The company also promotes a generic Treprostinil Injection with partner Sandoz and is developing L606, an investigational sustained-release liposomal treprostinil inhalation suspension.

Product overview

Liquidia Corporation is a biopharmaceutical company focused on rare cardiopulmonary diseases, operating a portfolio of commercial and pipeline products. The commercial portfolio includes YUTREPIA™ (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for PAH and PH-ILD launched in June 2025, and Treprostinil Injection, a generic formulation promoted with partner Sandoz. The pipeline includes L606, an investigational extended-release liposomal formulation of treprostinil administered twice-daily via nebulizer, currently in pivotal Phase 3 trials (Re-Spire). All products leverage the company's proprietary PRINT® technology platform for enhanced drug delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • YUTREPIA: FDA-approved inhaled dry-powder formulation of treprostinil for treatment of PAH and PH-ILD, delivered through a palm-sized device using PRINT technology
  • L606
  • Treprostinil Injection
  • PRINT

Products and services

  • YUTREPIA (treprostinil) Inhalation Powder FDA-approved inhaled dry-powder formulation of treprostinil indicated for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Delivered through a convenient, low-resistance, palm-sized device using Liquidia's proprietary PRINT technology, with particles 1.3 μm in size precisely engineered with a trefoil shape for enhanced deep-lung deposition. For patients with WHO Group 1 PAH and WHO Group 3 PH-ILD and the pulmonologists, PH specialists, and specialty pharmacies who treat them.
  • Treprostinil Injection Fully substitutable AP-rated generic formulation of Remodulin (treprostinil) Injection for treatment of pulmonary arterial hypertension (PAH). Liquidia promotes the product in the United States in conjunction with commercial partner Sandoz, Inc., which holds the ANDA with the FDA.

Quantifiable outcome

  • Reduced coughing and improved tolerability in PH-ILD patients over 24 weeks of treatment
  • +1 more outcomes

Companies that use Liquidia Technologies

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Liquidia Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Liquidia Technologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Pharmosa BiopharmcoreStrategic or Co-development PartnerPartnership to develop L606 (liposomal treprostinil inhalation suspension), an investigational sustained-release formulation of treprostinil administered twice-daily via rapid nebulization with a hand-held portable system for PAH and PH-ILD treatment.
  • Sandoz Inc.coreChannel Partner/ Reseller/ DistributorCommercial partnership for Treprostinil Injection promotion in the United States. Sandoz holds the ANDA with the FDA for the generic formulation while Liquidia promotes appropriate use of the product.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Liquidia Technologies competitors and assessment

Company assessment

Direct peers

  • United Therapeutics Corporation: Direct competitor and the incumbent in inhaled treprostinil therapy with Tyvaso and Tyvaso DPI for PAH and PH-ILD. Head-to-head competitor to YUTREPIA in the same patient population and same drug class, and also the plaintiff in ongoing patent litigation against Liquidia.

Emerging players

  • Gossamer Bio: Late-stage biopharma developing seralutinib (inhaled PDGF/CSF1R/VEGFR inhibitor) for PAH, including the Phase 3 TORREY study. Competes in the same PAH specialty channel and targets the same pulmonologists and PH specialists as YUTREPIA.
  • Aerami Therapeutics: Private biotech developing inhaled imatinib (AER-901) for severe pulmonary diseases including PAH. Competes with YUTREPIA for the same PAH specialist audience with a different mechanism and overlapping clinical development timelines.
  • Aerovate Therapeutics: Clinical-stage biopharma developing inhaled imatinib (AV-101) for PH-ILD. Same pulmonary hypertension patient focus as YUTREPIA but with a different mechanism (tyrosine kinase inhibitor), competing for the same PH-ILD prescriber mind-share.
  • Tenax Therapeutics: Clinical-stage company developing TNX-103 (oral levosimendan) for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Adjacent pulmonary hypertension franchise competing for the same specialist prescribers and clinical-development infrastructure as Liquidia.

Broad incumbents

  • Insmed Incorporated: Respiratory-focused biopharma with Arikayce (approved) and brensocatib (Phase 3) in non-CF bronchiectasis and other pulmonary indications. Not a direct competitor in PAH but a broad respiratory player pursuing adjacent specialty pulmonology markets and competing for similar talent and clinical site infrastructure.
  • Bayer AG: Markets Adempas (riociguat), the only approved therapy for chronic thromboembolic pulmonary hypertension (CTEPH) and an approved PAH therapy. A broad incumbent in the pulmonary hypertension space competing for prescriber share across multiple PH subtypes.
  • Merck & Co. Acquired Acceleron Pharma in 2021 to obtain Winrevair (sotatercept), the first activin signaling inhibitor approved for PAH. Represents a major new mechanism-based competitor that could shift PAH treatment paradigms and indirectly pressure YUTREPIA's market position.
  • Johnson & Johnson (Actelion): Acquired Actelion in 2017 to gain the leading oral PAH franchise (Opsumit/macitentan, Tracleer/ bosentan, Uptravi/selexipag). A broad incumbent that competes with YUTREPIA for PAH patient starts and physician attention across multiple lines of therapy.

Others

  • Pharmosa Biopharm: Liquidia's co-development partner for L606 (liposomal treprostinil inhalation suspension). Adjacent rather than directly competitive; develops and supplies the liposomal formulation used in Liquidia's Phase 3 Re-Spire study, making it a key enabling partner in Liquidia's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Liquidia Technologies social profiles

Digital presence

Liquidia Technologies compliance and trust

Trust signal

Compliance4 records

Liquidia Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Liquidia Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Liquidia Technologies funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Liquidia Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liquidia Technologies

What does Liquidia Technologies do?

Liquidia Corporation is a biopharmaceutical company that develops and commercializes inhaled therapeutics for rare cardiopulmonary diseases. Its lead commercial product is YUTREPIA (treprostinil) inhalation powder, an FDA-approved dry-powder inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), delivered via a palm-sized low-resistance device built on the company's proprietary PRINT particle engineering platform. The company also promotes a generic Treprostinil Injection with partner Sandoz and is developing L606, an investigational sustained-release liposomal treprostinil inhalation suspension.

Is Liquidia Technologies a public or private company?

Liquidia Technologies is a public company. It is classified as public and is currently operating.

When was Liquidia Technologies founded?

Liquidia Technologies was founded in 2004. It employs 251 to 500 people.

Where is Liquidia Technologies based?

Liquidia Technologies is headquartered in Morrisville, United States, in the North America region.

How does Liquidia Technologies make money?

Two revenue lines are on record. YUTREPIA Product Sales are the primary driver. The others are treprostinil Injection Promotion.

Who are Liquidia Technologies's main competitors?

United Therapeutics Corporation is listed as a direct peer. Emerging players are Gossamer Bio, Aerami Therapeutics, Aerovate Therapeutics and Tenax Therapeutics. Broad incumbents are Insmed Incorporated, Bayer AG, Merck & Co. and Johnson & Johnson (Actelion). Pharmosa Biopharm is listed as an others.

Does Liquidia Technologies have an API?

No public API is recorded for Liquidia Technologies.

What industry is Liquidia Technologies in?

Liquidia Technologies's product category is Pulmonary Hypertension Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAHAIAI, Inhalers (MDI/DPI/SMI). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooWill Revenue Growth And Wider Losses Change Liquidia (LQDA) Stock NarrativeLiquidia reported Q3 2026 revenue of $225.3 million and a net loss of $236.33 million, with nine-month revenue of $529.84 million and a loss of $108.74 million. The high revenue paired with wider losses signals pressure on cost structure and investment spending. The upcoming Jefferies Global Healthcare Conference on 17 November 2026 will address how this mix affects cash needs and investment pacing.Simply Wall StHow Q3 Results Will Impact Liquidia (LQDA) InvestorsLiquidia reported Q3 2026 revenue of $225.3 million and a net loss of $236.33 million, with a nine-month net loss of $108.74 million on $529.84 million in sales. The loss reflects heavy commercial and development spending, and the company projects $942.5 million revenue and $368.9 million earnings by 2029.Defense WorldNeedham & Company LLC Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) StockNeedham & Company raised its price target on Liquidia to $66 from $58, keeping a buy rating. The stock opened at $58.12, and the company reported a Q4 loss of $2.64 per share, missing the $0.96 consensus estimate, though revenue rose 314.9% year-over-year.Defense WorldRaymond James Financial Upgrades Liquidia (NASDAQ:LQDA) to Strong-BuyRaymond James upgraded Liquidia to strong-buy with a $77 target, up from $53. The company reported Q3 EPS of -$2.64, missing the $0.96 consensus, but revenue rose 314.9% year-over-year to $225.30 million. Analysts average a 'Hold' rating with a $74.38 target.Quiver QuantitativeLiquidia Rises as Strong YUTREPIA Growth and a Fresh Analyst Upgrade Boost Sentiment | LQDA Stock NewsLiquidia Corporation's stock rose 5.3% after its third-quarter update and an analyst upgrade. The move reflects strong YUTREPIA sales growth and record October shipments, with insiders selling shares and hedge funds adding positions. Analysts have set a median price target of $79.Investing.comBofA raises Liquidia stock price target on strong PAH momentumBofA Securities raised its price target on Liquidia Technologies to $54 from $42, maintaining a Neutral rating. The firm increased Yutrepia PAH estimates by mid-single-digit to low-double-digit percentages after Q3 sales of $222.7 million, in line with preliminary figures. The stock trades at $51.40, approaching the new target.TradingViewNeedham maintains Liquidia at Buy, raises price target to $66 from $58Needham maintained Liquidia at Buy and raised its price target to $66 from $58, a 13.8% increase. The target implies 28.4% upside from the Nov 10 close of $51.40. Recent analyst price targets on Liquidia range from $33 to $87.Simply Wall StLiquidia (LQDA) Climbed, But What Is Driving Attention Now?Liquidia reported Q3 2026 results showing strong YUTREPIA traction and a legal settlement with United Therapeutics, driving an 87.73% stock gain over 30 days. Analysts peg fair value at $33, implying overvaluation, while a DCF model suggests the stock trades 69.3% below estimated cash flow value.Seeking AlphaLiquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029 (NASDAQ:LQDA)Liquidia plans to complete Phase 3 enrollment for its PH-ILD program in 2028 and submit the L606 NDA in 2029. The company reported five consecutive quarters of growth in prescriptions, revenue, and adjusted EBITDA, and cited a recent settlement that removed litigation overhang.BenzingaLiquidia Q3 2026 Earnings Call Transcript - Liquidia (NASDAQ:LQDA)Liquidia reported Q3 2026 net product sales of $222.7 million, up 31%, with adjusted EBITDA of $140.5 million. A one-time settlement charge of $389.7 million caused a GAAP net loss of $236.3 million. The company plans to provide 2027 guidance in early January.